[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hpv-vaccination\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hpv-vaccination":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,41,63,92,122,149,184,204,226],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100570212","parents-hpv-stories-100570212",false,"NCT06704308","Parents' HPV Stories","Development and Preliminary Evaluation of a Multilevel Intervention to Increase HPV Vaccine Confidence Among Parents of Youth in Rural KY","Inclusion Criteria:\n\n* status as a mother or female guardian of an 11-17-year-old adolescent\n* status as a U.S. resident\n* self-reported ability to read English\n* self-reported HPV vaccine hesitant using established methodology\n\nExclusion Criteria:\n\n\\-",true,"FEMALE","18 Years",{"count":20,"type":21},58,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate the feasibility of intervention implementation in two clinics in rural KY, and its preliminary efficacy with regards to increasing vaccine confidence in a sample of vaccine hesitant parents.\n\nHypothesis: Parents will report increased vaccine confidence scores post-intervention.\n\nData from this study will provide preliminary data for a larger scale evaluation of the intervention.\n\nParticipants will be asked to complete surveys, view a web-based intervention and then visit with their child's healthcare provider.",[27],"HPV Vaccination","NOT_YET_RECRUITING","2026-06-10",{"date":31,"type":32},"2026-06-12","ACTUAL",{"date":34,"type":21},"2026-07",{"date":36,"type":21},"2026-11",{"name":38,"class":39},"Anne E Ray","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":18,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":59,"leadSponsor":61,"locationsCount":40},"100642217","microvideos-for-improving-hpv-vaccination-among-childhood-cancer-survivors-100642217","NCT07648953","Microvideos for Improving HPV Vaccination Among Childhood Cancer Survivors","Inclusion Criteria:\n\n* Eligible participants include cancer survivors who are currently ages 18-26 years and who were diagnosed with childhood cancer (ages 0-26 at diagnosis) in the past ten years.\n* Currently use Facebook or willing to create a Facebook account to use for the duration of the study.\n* At the time of enrollment, have not completed all recommended doses of the HPV vaccine.\n\nExclusion Criteria:\n\n* Unable to speak and understand English.\n* Participants who take part in the Aim 1 focus groups will be ineligible for the Aim 2 social media group.\n* Participants who are fully vaccinated for HPV will be ineligible as the goal of Aim 2 is to evaluate the feasibility of the social media campaign for improving vaccine intention among HPV unvaccinated individuals.","ALL","26 Years",{"count":50,"type":21},55,[24],"This exploratory mixed-methods study aims to examine receipt of treatment and decision-making among rural cancer patients in Utah. Guided by Conceptual Model of Healthcare Access, the study will integrate, survey and cancer registry data with patient interviews to better understand how travel burden, socioeconomic conditions, health literacy, and other contextual factors shape treatment location and access to care . While the setting of this research is specific to Utah, a state with vast rural regions and only one National Cancer Institute (NCI)-designated cancer center, the findings may inform policy and practice improvements in other states with similar geographic and healthcare infrastructure. Thus, the study has potential relevance for advancing rural cancer equity nationwide.\n\nUnderstanding how rural cancer patients make treatment decisions is essential to addressing persistent disparities in cancer care access and outcomes. While geographic barriers and structural inequities are well-documented, less is known about the individual and contextual factors that shape patients' choices about where and how to receive treatment. This mixed-methods study will examine receipt of treatment, decision-making, and patient experience among rural cancer patients in Utah, with attention to travel burden, referral pathways, health literacy, and perceived barriers to care.",[27],"RECRUITING","2026-06-09",{"date":57,"type":32},"2026-06-15",{"date":34,"type":21},{"date":60,"type":21},"2027-05",{"name":62,"class":39},"University of Utah",{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":16,"sex":47,"minAge":18,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":40},"100642446","trial-in-hpv-prevention-for-the-us-vietnamese-community-100642446","NCT07637630","Trial in HPV Prevention for the U.S. Vietnamese Community","Applying the Multiphase Optimization Strategy to Develop and Test a Culturally-Relevant Digital Health Intervention Targeting HPV Vaccination Among U.S. Vietnamese","HERO","Inclusion Criteria:\n\n* Self-identify as U.S. Vietnamese.\n* Are the parent of a youth ages 9-18 who have not initiated the HPV vaccine series. Only one parent per household will be able to participate.\n* Have lived in the U.S. for 12 months or more.\n\nExclusion Criteria:\n\n* Planning to move out of the U.S. within the next 6 months.\n* Not fluent in either spoken and written Vietnamese or spoken and written English.\n* Inability to provide informed consent.",{"count":72,"type":21},96,[24],"The purpose of the HERO study is to leverage the Multiphase Optimization Strategy (MOST) framework to conduct a pilot trial testing four different intervention components (expert video, self-persuasion, narrative storytelling, and motivational interviewing) targeting HPV vaccination among U.S. Vietnamese.\n\nPRIMARY AIM To assess the feasibility and acceptability of each of the four digital HERO intervention components in a pilot optimization trial using the MOST framework. Using a highly efficient design, the study team will randomize 96 Vietnamese parents of unvaccinated adolescents to receive 0 to 4 HERO components. The study team will establish the feasibility (reach, retention, adherence) and acceptability (usability, satisfaction, usefulness, cultural relevance) of each component (expert video, self-persuasion, narrative storytelling, and motivational interviewing).\n\nSECONDARY AIM To investigate effects of each component on HPV vaccination outcomes and psychosocial mediators. The study team will examine the effects on HPV vaccination (initiation and intention) and psychosocial mediators.",[76,27],"HPV-related Cancers",[78,79,80,81,82,83],"HPV vaccination","digital health intervention","U.S. Vietnamese","MOST framework","behavioral intervention","adolescent vaccination",{"date":85,"type":32},"2026-06-11",{"date":87,"type":32},"2026-05-01",{"date":89,"type":21},"2029-06-30",{"name":91,"class":39},"Northwestern University",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":16,"sex":47,"minAge":4,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":103,"conditions":104,"keywords":108,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":4},"100643606","addressing-hpv-vaccine-hesitancy-by-co-designing-a-digital-health-intervention-100643606","NCT07632963","Addressing HPV Vaccine Hesitancy by Co-Designing a Digital Health Intervention","HPV-Kompassen: a Mixed-Methods Single-Arm Cluster Feasibility Study of a Co-Designed Web-Based Intervention To Strengthen HPV Vaccine Confidence and Uptake in Stockholm, Sweden","HPV-END-IT","We will aim to recruit 6-8 compulsory schools in Stockholm County to serve as clusters.\n\nAll Year 5 pupils and their caregivers in the study schools are invited.\n\nInclusion Criteria:\n\n* The school provides education to pupils in school year 5 and is scheduled to be open throughout the pilot trial period\n* The school is located in an area with HPV vaccine uptake \\\u003C85.2% (the Stockholm regional average)\n* The head principal and school nurse both consent to participate\n* The school has the capacity to implement the intervention\n\nExclusion Criteria:\n\n* Failure to meet the inclusion criteria",{"count":101,"type":21},100,[24],"This study looks at a digital platform that supports HPV vaccination in schools. The goal is to see if it is useful, easy to use, and practical in real school settings, especially in areas where fewer people get vaccinated.\n\nResearchers will give Year 5 pupils (aged 11-12) and their parents or caregivers access to the platform. It provides clear, trusted information about the HPV vaccine for young people, parents, and school nurses. The aim is to make the vaccine easier to understand and to help answer any questions or concerns.\n\nAfter using the platform, participants will be asked to share their thoughts.",[105,106,107,27],"HPV","Vaccine Acceptance","Vaccine Decision Making",[109,110,111,112],"Human papilloma virus","HPV vaccine","Vaccine uptake","Vaccine confidence","2026-06-02",{"date":115,"type":32},"2026-06-08",{"date":117,"type":21},"2026-08",{"date":119,"type":21},"2027-06",{"name":121,"class":39},"Karolinska Institutet",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":16,"sex":47,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":40},"100605582","empowering-vietnamese-americans-100605582","NCT07164391","Empowering Vietnamese Americans","Empowering Vietnamese Americans: A Culture-Centric Digital Storytelling Intervention to Boost HPV Vaccination","Inclusion Criteria: An individual is eligible if they:\n\n* Self-identify as a Vietnamese American or immigrant woman aged 18 years or older\n* Are the primary caregiver of at least one unvaccinated child aged 11-14 years\n* Can speak and read English or Vietnamese\n* Agree to receive text messages and\u002For emails related to project activities during the study period\n\nExclusion Criteria:\n\n* inability\u002Funwillingness to provide consent.",{"count":130,"type":21},60,[24],"The goal of this clinical trial is to learn whether short videos can help Vietnamese American mothers decide to vaccinate their children against HPV (human papillomavirus). The study will explore: (1) whether different interventions influence mothers' intentions and decisions regarding HPV vaccination for their children; (2) how mothers perceive and engage with the videos; and (3) how many children receive the HPV vaccine after their mothers watch the videos.\n\nParticipants will be randomly assigned to one of two groups: (a) watch four short digital stories about the HPV vaccine created by Vietnamese mothers; or (b) watch four short videos on general teen health topics such as mental health and social media use. Participants will complete brief surveys and their child's HPV vaccination status will be checked two months after the intervention.",[27,134],"Cancer Prevention",[105,136,137,138,139],"cancer prevention","Vietnamese American","youth","digital storytelling","2026-05-18",{"date":142,"type":32},"2026-05-20",{"date":144,"type":32},"2025-10-01",{"date":146,"type":21},"2027-11-30",{"name":148,"class":39},"Michigan State University",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":16,"sex":47,"minAge":157,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":163,"conditions":164,"keywords":170,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":40},"100612694","phase-4-a-trial-to-establish-non-inferiority-of-immunogenicity-of-a-single-dose-of-cervavac-quadrivalent-hpv-vaccine-compared-to-the-gardasil-quadrivalent-vaccine-among-girls-and-boys-aged-9-to-14-years-and-in-girlswomen-aged-15-to-20-years-in-zambia-100612694","NCT07256912","A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls\u002FWomen Aged 15 to 20 Years in Zambia","A Randomized, Active Controlled, Assessors-blind Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls\u002FWomen Aged 15 to 20 Years in Zambia","CervALONE","Inclusion Criteria:\n\n1. Girl\u002Fwoman between 9 and 20 years of age and boy between the age of 9 and 14 years at the time of recruitment.\n2. Participant willing to sign a written informed consent (for participants 18 years of age and above).\n3. Parent (s) willing to provide written informed consent and participant is willing to sign written assent form for participation (for participants below 18 years of age at the time of eligibility assessment).\n4. Participant or parent (s) willing to comply with all study requirements.\n5. Participants who are determined by Medical History (MH), Physical Examination (PE) and clinical judgment of the Investigator to be eligible for inclusion in the study.\n\nExclusion Criteria:\n\n1. Participants who are sexually active and missed their last menstrual period will have a urine pregnancy test and will be excluded if found pregnant.\n2. Participant has a known history of prior vaccination with any HPV vaccine.\n3. Participant known to be HIV positive (no routine HIV testing will be performed unless clinically indicated)\n4. Participant currently enrolled in any other clinical studies of investigational products.\n5. Participant with a current diagnosis or prior history of genital warts or treatment of genital warts.\n6. Participant with a current diagnosis or prior history of cervical intraepithelial neoplasia (CIN) or cervical cancer.\n7. Participant has a history of any allergic diseases or severe allergic reaction to any agent\u002Fvaccine product (e.g., swelling of the mouth and throat, difficulty in breathing, hypotension, or shock).\n8. Participant has had an acute illness (moderate or severe) and\u002For fever (body temperature ≥ 38°C or ≥ 100.4 °F) at the time of vaccination or during the 72 hours prior to the vaccination.\n9. Bleeding diathesis or uncontrolled condition associated with prolonged bleeding that would, in the opinion of the Investigator, contraindicate IM injection.\n10. Participant has history of major congenital defects or illness that requires medical therapy, as determined by MH or clinical assessment.\n11. Participant has had chronic administration (defined as more than 14 days) of high doses of corticosteroids (prednisone or equivalent at a dose of \\>0.5 mg\u002Fkg\u002Fday), cytotoxic agents or radiotherapy or immunoglobulins, immunosuppressants or other immune-modifying drugs in last 3 months or planned at any time during the study.\n12. Participant has history of receiving a blood transfusion or other blood products in three months prior to screening.\n13. Planned administration of a vaccine not foreseen by the study protocol within 14 days before and 14 days after any dose of study vaccine except TT given for emergency use and any vaccine mandated by government program.\n14. Participant has history of any major pulmonary, cardiovascular, renal, neurological, metabolic, gastro-intestinal, hepato-biliary, hematological functional abnormality, mental or physical disability, blood dyscrasia or any condition which in the opinion of the Investigator might interfere with the evaluation of the study objectives.\n15. Participant has history of any cancer, organ transplant or any other immune system disease.\n16. Individuals who, in the opinion of the investigator, are unlikely to be compliant to all study procedures","9 Years","20 Years",{"count":160,"type":21},1266,[162],"PHASE4","The goal of this study is to compare the immune response of the single dose of the CERVAVAC vaccine with the single dose of Gardasil vaccine in girls\u002Fwomen aged 9 to 20 and boys aged 9 to 14 at 6 months, 12 months and 24 months post vaccination. The vaccine will be given randomly to the boys and girls\u002Fwomen in these age group and they will be followed up to check the immune status developed in them after vaccination. The status of immune response developed by the two differnet vaccines will be compared in these group of participants of the study.",[165,27,166,167,168,169],"Vaccine Effectiveness","Single Dose","Immunogenicity","Cervical Cancer Prevention","Quadrivalent HPV Vaccine",[105,171,172,173,174],"VACCINE","SINGLE DOSE","cervical cancer prevention","Quadrivalent HPV vaccine","2026-03-23",{"date":177,"type":32},"2026-03-24",{"date":179,"type":21},"2026-04-01",{"date":181,"type":21},"2029-01-15",{"name":183,"class":39},"International Agency for Research on Cancer",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":16,"sex":47,"minAge":18,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":40},"100616153","culturally-targeted-health-communication-and-receptivity-to-the-human-papillomavirus-vaccine-among-parents-in-flint-mi-100616153","NCT07301905","Culturally Targeted Health Communication and Receptivity to the Human Papillomavirus Vaccine Among Parents in Flint, MI","Culturally Targeted Messaging and Parental Receptivity to the Human Papillomavirus Vaccine","Inclusion Criteria:\n\n* Identify as Black\u002FAfrican American or White\u002FCaucasian\n* Have at least one daughter who is between 8-17 years of age, who is not currently pregnant, and who has not received any doses of the HPV vaccine\n\nExclusion Criteria:\n\n* N\u002FA",{"count":192,"type":21},265,[24],"The goal of this clinical trial is to learn if culturally targeted messaging about the human papillomavirus (HPV) increases receptivity to the HPV vaccine among African American parents of vaccine-eligible daughters. The main question it aims to answer is:\n\n• Does culturally targeted messaging increase African American parents' intentions to vaccinate their daughter against HPV?\n\nResearch will compare culturally targeted messaging to general, educational messaging and no messaging.\n\nParticipants will:\n\n* View culturally targeted messages, education-only messages, or no messages about the HPV vaccine\n* Report their intentions to vaccinate their daughter against HPV\n* Report whether they have initiated HPV vaccination for their daughter six months later",[27],"2026-03-11",{"date":198,"type":32},"2026-03-13",{"date":200,"type":32},"2024-11-17",{"date":202,"type":21},"2026-06",{"name":148,"class":39},{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":213,"phases":4,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":4},"100601660","study-for-prevention-of-cervical-cancer-in-spain-100601660","NCT07113379","Study for Prevention of Cervical Cancer in Spain","REVIVE","Inclusion Criteria:\n\n* Female patients diagnosed with squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix.\n* Diagnosis established between 2019 and 2024.\n\nExclusion Criteria:\n\n* Patients aged below 18 years at diagnosis.\n* Diagnosis of other cervical cancer histologies (e.g., neuroendocrine tumors, sarcoma, lymphoma).\n* Patents with significant cognitive impairment precluding informed consent for data utilization, where applicable.\n* Patients with incomplete medical records relevant to the study variables.",{"count":212,"type":21},200,"OBSERVATIONAL","The REVIVE study aims to analyze the current status of Human Papillomavirus (HPV) vaccination programs and cervical cancer screening strategies in Spain. Its objective is to gain a comprehensive understanding of the effectiveness of these preventive measures, as well as to identify the main barriers to access and the existing inequalities in care. The study will also examine the impact of misinformation on population engagement and on the overall equity of the prevention system.\n\nDespite significant advances in both vaccination and screening efforts, cervical cancer remains a major public health concern in Spain. In 2024 alone, 2,259 new cases were diagnosed, that incidence has remained relatively stable in recent years, even decades. Mortality rates have also shown little change, with over 600 deaths annually, totaling nearly 10,000 in the last 15 years.\n\nTo address this, the study plans to include approximately 200 patients diagnosed with cervical cancer in Spain between 2019 and 2024. It is a retrospective, observational, and non-interventional study. Data will be collected from existing medical records and supplemented with a specific questionnaire administered to the participating patients.",[216,27],"Cervical Cancer Screening","2025-08-07",{"date":219,"type":32},"2025-08-08",{"date":221,"type":21},"2025-10",{"date":223,"type":21},"2026-10",{"name":225,"class":39},"Clinica Universidad de Navarra, Universidad de Navarra",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":16,"sex":47,"minAge":157,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":40},"100592766","integrated-hpv-vaccination-and-adolescent-health-in-ivory-coast-100592766","NCT06997705","Integrated HPV Vaccination and Adolescent Health in Ivory Coast","Strengthening HPV Vaccination and Adolescent Health Research Program (SHARP) in Ivory Coast","SHARP-CI","Inclusion Criteria for adolescents:\n\n* Age: 9 to 15;\n* Residence in the study regions;\n* Parental or guardian permission is required;\n* Provides assent and agrees to participate in the study.\n\nInclusion criteria for Parents\u002Fcaregivers:\n\n* Be the parent or legal guardian of an adolescent aged 9 to 15 years;\n* Residence in the study regions;\n* Provides informed consent and agrees to participate in the study.\n\nExclusion Criteria:\n\n* People who have time constraints;\n* those who do not speak French or the prominent dialects in study regions;\n* those unable to participate because ill, intoxicated or appearing psychologically impaired;\n* those residing outside study health regions;\n* those who do not provide consent\u002Fassent to participate.","110 Years",{"count":236,"type":21},3384,[24],"Background: Cervical cancer is a serious global public health problem, particularly in sub-Saharan Africa, where it is the leading cause of cancer in women, with around 70,722 new cases each year. Vaccination against human papillomavirus (HPV) prevents cervical cancer and is usually given to children around 9 to 15 years of age. HPV vaccination has been incorporated into many countries' Expanded Programs on Immunization, but often faces optimization and uptake challenges. SHARP is an implementation research initiative in Tanzania, Nigeria, and Côte d'Ivoire that is looking at the potential of combining HPV vaccination with with adolescent primary care\u002Fpreventive health services - how this might work and its effect on the uptake of the HPV vaccine and other services.\n\nObjective: To describe the feasibility, acceptability, effectiveness and sustainability of a locally-designed integrated adolescent health service package, including HPV vaccination in Cote d'Ivoire. Specifically, this study aims to optimize existing primary health care approaches, making service delivery not only more convenient but also more effective in addressing the specific needs of adolescents-both in school and out of school-across schools, communities, and health facilities.\n\nMethods: This is a quasi-experimental research study using the difference-in-difference method between an intervention group and a comparison group over time. It will use mixed methods drawing on quantitative surveys, qualitative interviews, service time motion assessment, and administrative data. The study will be conducted in two regions, each with an intervention and comparison district. The optimized adolescent integrated health intervention will be implemented in the intervention districts with routine service provision in comparison areas. Monthly administrative service coverage data and baseline and endline surveys will be conducted in up to 3502 households with 1626 parents\u002Fcaregivers and 1626 adolescents will assess effectiveness by looking at changes in service uptake and coverage, as well in knowledge, attitudes, and practices towards HPV vaccination and integrated services. At endline, up to 132 in-depth interviews will be conducted with program managers, health officials, service providers, school authorities, community influencers and leaders, and adolescents and parents\u002Fcaregivers will assess feasibility, acceptability and sustainability.",[240,27,241],"Integrated Care","Adolescent","2025-05-22",{"date":244,"type":32},"2025-05-30",{"date":246,"type":32},"2025-03-16",{"date":248,"type":21},"2025-09",{"name":250,"class":39},"Jhpiego"]